

Stephan Windecker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8451476/publications.pdf>

Version: 2024-02-01

811
papers

120,712
citations

418

132
h-index

138

331
g-index

829
all docs

829
docs citations

829
times ranked

50399
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
2	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
3	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
4	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
5	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
6	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
7	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
8	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
9	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	1.0	3,465
10	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
11	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	1.0	2,649
12	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	1.2	2,558
13	Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1321-1331.	13.9	2,249
14	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
15	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	0.6	2,164
16	Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. <i>Lancet</i> , The, 2007, 369, 667-678.	6.3	1,879
17	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S45-S60.	0.6	1,605
18	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1438-1454.	1.2	1,560

#	ARTICLE	IF	CITATIONS
19	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet, The</i> , 2007, 370, 937-948.	6.3	1,329
20	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	0.6	1,313
21	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , 2012, 33, 2403-2418.	1.0	900
22	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	6.3	840
23	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
24	Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 6-23.	0.4	783
25	Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. <i>New England Journal of Medicine</i> , 2013, 368, 1083-1091.	13.9	781
26	Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation. <i>Circulation</i> , 2007, 115, 2426-2434.	1.6	766
27	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2017, 377, 2419-2432.	13.9	764
28	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 162.	3.8	762
29	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2011, 57, 253-269.	1.2	735
30	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2010, 363, 136-146.	13.9	608
31	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet, The</i> , 2008, 372, 1163-1173.	6.3	607
32	Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18â€Fr) CoreValve ReValving System: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. <i>EuroIntervention</i> , 2008, 4, 242-249.	1.4	576
33	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2018, 392, 940-949.	6.3	555
34	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. <i>European Heart Journal</i> , 2010, 31, 943-957.	1.0	548
35	Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization. <i>New England Journal of Medicine</i> , 2005, 353, 653-662.	13.9	547
36	Predictors of Permanent Pacemaker Implantation in Patients With Severe Aortic Stenosis Undergoing TAVR. <i>Journal of the American College of Cardiology</i> , 2014, 64, 129-140.	1.2	536

#	ARTICLE	IF	CITATIONS
37	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	0.6	510
38	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
39	Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1134-1140.	1.2	468
40	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. <i>Lancet, The</i> , 2016, 388, 2479-2491.	6.3	451
41	Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis. <i>Circulation</i> , 2009, 120, 391-399.	1.6	441
42	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , 2018, 137, 2635-2650.	1.6	435
43	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	1.0	433
44	Percutaneous Closure of Patent Foramen Ovale in Patients With Paradoxical Embolism. <i>Circulation</i> , 2000, 101, 893-898.	1.6	416
45	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
46	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1419-1434.	1.1	385
47	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	1.4	367
48	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	13.9	362
49	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , 2012, 33, 1214-1222.	1.0	359
50	Sirolimus-Eluting Stents Associated With Paradoxical Coronary Vasoconstriction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 231-236.	1.2	356
51	Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents. <i>Circulation</i> , 2012, 125, 1110-1121.	1.6	341
52	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2017, 38, 3382-3390.	1.0	335
53	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. <i>Lancet, The</i> , 2011, 378, 1940-1948.	6.3	321
54	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	1.0	317

#	ARTICLE	IF	CITATIONS
55	Promotion of Collateral Growth by Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Coronary Artery Disease. <i>Circulation</i> , 2001, 104, 2012-2017.	1.6	311
56	A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1373-1380.	1.2	307
57	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. <i>New England Journal of Medicine</i> , 2018, 379, 1699-1710.	13.9	303
58	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2998-3008.	1.2	302
59	Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. <i>Journal of the American College of Cardiology</i> , 2004, 44, 750-758.	1.2	299
60	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. <i>European Heart Journal</i> , 2019, 40, 3143-3153.	1.0	297
61	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 777-789.	1.1	296
62	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. <i>BMJ</i> , The, 2014, 348, g3859-g3859.	3.0	291
63	Evaluation of Multidimensional Geriatric Assessment as a Predictor of Mortality and Cardiovascular Events After Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 489-496.	1.1	282
64	Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2330-2339.	1.2	280
65	Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 777.	3.8	278
66	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, 3503-3512.	1.0	275
67	Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). <i>European Heart Journal</i> , 2013, 34, 684-692.	1.0	272
68	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a1331-a1331.	2.4	270
69	Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. <i>European Heart Journal</i> , 2018, 39, 687-695.	1.0	269
70	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet</i> , The, 2015, 386, 655-664.	6.3	261
71	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
72	Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. <i>Circulation</i> , 2016, 133, 650-660.	1.6	260

#	ARTICLE	IF	CITATIONS
73	Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. <i>EuroIntervention</i> , 2010, 5, 871-874.	1.4	257
74	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	1.4	251
75	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2021, 385, 1643-1655.	13.9	247
76	Outcomes After Current Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 155-165.	1.1	246
77	Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1086-1106.	1.2	242
78	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	1.2	240
79	An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. <i>European Heart Journal</i> , 2010, 31, 165-176.	1.0	239
80	Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1748-1752.	1.2	232
81	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 2111-2122.	6.3	224
82	Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	222
83	Late Coronary Stent Thrombosis. <i>Circulation</i> , 2007, 116, 1952-1965.	1.6	218
84	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	1.2	218
85	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. <i>Lancet, The</i> , 2011, 377, 1241-1247.	6.3	216
86	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	1.2	216
87	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	6.3	215
88	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	13.9	207
89	Transcatheter Aortic Valve Replacement in Europe. <i>Journal of the American College of Cardiology</i> , 2013, 62, 210-219.	1.2	199
90	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 56, 272-277.	1.2	198

#	ARTICLE	IF	CITATIONS
91	Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. <i>European Heart Journal</i> , 2014, 35, 2672-2684.	1.0	197
92	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction TROFI II trial. <i>European Heart Journal</i> , 2016, 37, 229-240.	1.0	197
93	Impact of Permanent Pacemaker Implantation on Clinical Outcome Among Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 493-501.	1.2	195
94	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 130-139.	13.9	194
95	Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1543-1552.	1.6	190
96	Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 1619-1628.	6.3	189
97	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	1.0	187
98	Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. <i>Lancet, The</i> , 2017, 390, 773-780.	6.3	187
99	Very Late Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1901-1914.	1.2	186
100	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1771.	3.8	185
101	Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. <i>European Heart Journal</i> , 2005, 26, 1180-1187.	1.0	183
102	Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1121-1131.	1.2	183
103	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document#. <i>EuroIntervention</i> , 2012, 8, 782-795.	1.4	182
104	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
105	Standardized End Point Definitions for Coronary Intervention Trials. <i>European Heart Journal</i> , 2018, 39, 2192-2207.	1.0	179
106	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001441.	1.4	172
107	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	1.0	171
108	Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2011, 123, 2819-2828.	1.6	169

#	ARTICLE	IF	CITATIONS
109	The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?. <i>European Heart Journal</i> , 2015, 36, 1651-1659.	1.0	168
110	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <i>European Heart Journal</i> , 2015, 36, 490-500.	1.0	168
111	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. <i>EuroIntervention</i> , 2013, 8, 1362-1371.	1.4	168
112	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet, The</i> , 2019, 393, 2503-2510.	6.3	166
113	Paradoxical Embolism. <i>Journal of the American College of Cardiology</i> , 2014, 64, 403-415.	1.2	165
114	Long-Term Propensity Score-Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical Embolism. <i>Circulation</i> , 2012, 125, 803-812.	1.6	160
115	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardiothoracic Surgery</i> , 2017, 52, 408-417.	0.6	160
116	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1451-1461.	1.1	160
117	Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia. <i>Circulation</i> , 2001, 104, 928-933.	1.6	158
118	Incidence and Predictors of Atrioventricular Conduction Impairment After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2010, 106, 1473-1480.	0.7	158
119	Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2011, 7, 541-548.	1.4	156
120	Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. <i>European Heart Journal</i> , 2016, 37, 2029-2036.	1.0	153
121	4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1617-1625.	1.2	152
122	Stable coronary artery disease: revascularisation and invasive strategies. <i>Lancet, The</i> , 2015, 386, 702-713.	6.3	152
123	Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1297-1308.	1.2	152
124	Clinical Outcomes of Patients With Severe Aortic Stenosis at Increased Surgical Risk According to Treatment Modality. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2151-2162.	1.2	150
125	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2018, 39, 1172-1180.	1.0	150
126	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving System-A Bern-Rotterdam Study. <i>American Heart Journal</i> , 2010, 159, 323-329.	1.2	149

#	ARTICLE	IF	CITATIONS
127	Impact of Stent Overlap on Angiographic and Long-Term Clinical Outcome in Patients Undergoing Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1178-1188.	1.2	146
128	Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 937-946.	1.1	145
129	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
130	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	3.0	144
131	Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1018-1030.	1.2	143
132	Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 845-853.	1.2	141
133	Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013, 34, 1894-1905.	1.0	140
134	Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2530-2540.	1.0	140
135	Randomized Comparison of a Titanium-Nitride-Oxide-Coated Stent With a Stainless Steel Stent for Coronary Revascularization. <i>Circulation</i> , 2005, 111, 2617-2622.	1.6	139
136	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. <i>European Heart Journal</i> , 2012, 33, 3098-3104.	1.0	138
137	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. <i>Lancet, The</i> , 2019, 394, 1243-1253.	6.3	138
138	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137
139	SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of Sirolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial. <i>European Heart Journal</i> , 2011, 32, 3115-3127.	1.0	136
140	Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). <i>Journal of the American College of Cardiology</i> , 2019, 74, 2452-2462.	1.2	135
141	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 977-987.	1.0	134
142	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	1.2	132
143	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020, 16, 371-379.	1.4	132
144	Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. <i>Journal of the American College of Cardiology</i> , 2005, 45, 377-380.	1.2	128

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
146	Acute coronary syndromes in young patients: Presentation, treatment and outcome. <i>International Journal of Cardiology</i> , 2011, 148, 300-304.	0.8	126
147	Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents. <i>Circulation</i> , 2011, 124, 612-623.	1.6	122
148	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002230.	1.4	122
149	Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. <i>European Heart Journal</i> , 2011, 32, 2454-2463.	1.0	121
150	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	1.0	120
151	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2330-2344.	1.2	117
152	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2860-2868.	1.2	116
153	Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. <i>American Heart Journal</i> , 2011, 161, 1114-1124.	1.2	115
154	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. <i>Atherosclerosis</i> , 2012, 221, 106-112.	0.4	115
155	The Electrocardiogram After Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1269-1276.	1.1	114
156	Vascular Tissue Reaction to Acute Malapposition in Human Coronary Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 20-29.	1.4	112
157	Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. <i>European Heart Journal</i> , 2014, 35, 1949-1956.	1.0	110
158	Age-Related Differences in the Use of Guideline-Recommended Medical and Interventional Therapies for Acute Coronary Syndromes: A Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 510-516.	1.3	109
159	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the 'All-Comers' LEADERS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 47-56.	1.4	109
160	Transcranial Doppler-detected cerebral embolic load during transcatheter aortic valve implantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 41, 778-784.	0.6	108
161	Atrial Fibrillation and Aortic Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 77-84.	1.4	108
162	Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1400-1411.	1.1	108

#	ARTICLE	IF	CITATIONS
163	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002358.	1.4	107
164	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020, 41, 1839-1851.	1.0	106
165	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2639-2654.	1.0	105
166	Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. <i>European Heart Journal</i> , 2015, 36, 120-128.	1.0	104
167	Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2013, 34, 3437-3450.	1.0	102
168	European Experience With the Second-Generation Edwards SAPIEN XT Transcatheter Heart Valve in Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 657-669.	1.1	102
169	Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2308-2317.	1.1	102
170	The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2221-2232.	1.2	101
171	Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. <i>Lancet, The</i> , 2018, 392, 737-746.	6.3	101
172	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	1.2	101
173	Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. <i>International Journal of Cardiology</i> , 2007, 120, 212-220.	0.8	100
174	Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. <i>European Heart Journal</i> , 2012, 33, 1334-1343.	1.0	100
175	Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. <i>EuroIntervention</i> , 2012, 8, 62-70.	1.4	100
176	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , 2016, 134, 698-709.	1.6	99
177	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1436-1446.	1.1	99
178	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 432-441.	1.1	98
179	Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. <i>European Heart Journal</i> , 2016, 37, 524-535.	1.0	98
180	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	3.0	97

#	ARTICLE	IF	CITATIONS
181	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. <i>European Heart Journal</i> , 2020, 41, 2731-2742.	1.0	97
182	Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2627-2638.	1.0	96
183	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 55-63.	1.1	96
184	Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1994-2003.	1.1	96
185	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. <i>Journal of the American College of Cardiology</i> , 2022, 79, 448-461.	1.2	96
186	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , 2017, 184, 81-87.	1.2	95
187	Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 905-927.	1.2	95
188	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement. <i>Circulation</i> , 2021, 143, 104-116.	1.6	94
189	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	1.0	93
190	Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2143-2151.	1.2	92
191	Aortic Root Dimensions Among Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 72-83.	1.1	92
192	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2016, 12, 1239-1245.	1.4	92
193	Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, 1304-1311.	1.0	90
194	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	1.0	89
195	Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003255.	1.4	88
196	Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2018, 360, k504.	2.4	86
197	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 577-587.	2.3	85
198	Edge-to-Edge Mitral Valve Repair With Extended Clip Arms. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1356-1365.	1.1	84

#	ARTICLE	IF	CITATIONS
199	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
200	Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1113.	3.8	82
201	Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. <i>European Heart Journal</i> , 2016, 37, 3386-3395.	1.0	80
202	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
203	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> . 2021. 42. 1254-1269.	1.0	78
204	Late Results After Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism Using the Amplatzer PFO Occluder Without Intraprocedural Echocardiography. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 116-123.	1.1	77
205	Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. <i>Heart</i> , 2010, 96, 967-973.	1.2	77
206	The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. <i>European Heart Journal</i> , 2015, 36, 2167-2176.	1.0	77
207	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	1.0	77
208	Clinical Impact of Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	75
209	Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction. <i>Circulation Research</i> , 2016, 119, 481-490.	2.0	75
210	Improvement of Risk Prediction After Transcatheter Aortic Valve Replacement by Combining Frailty With Conventional Risk Scores. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 395-403.	1.1	75
211	Chronic stable coronary artery disease: drugs vs. revascularization. <i>European Heart Journal</i> , 2010, 31, 530-541.	1.0	74
212	Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1123-1131.	1.2	73
213	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
214	Coronary Collateral Function Long After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2007, 49, 15-20.	1.2	70
215	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq1 1 0.784314 rgBT /Over Patients Enrolled in Contemporary Coronary Stent Trials. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 645-653.	1.1	70
216	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70

#	ARTICLE	IF	CITATIONS
217	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	0.4	70
218	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 375-388.	1.2	70
219	Percutaneous Management of Vascular Complications in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 515-524.	1.1	69
220	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
221	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. <i>JAMA Cardiology</i> , 2016, 1, 795.	3.0	68
222	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. <i>European Heart Journal</i> , 2014, 35, 795-807.	1.0	67
223	Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	67
224	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2020, 142, 441-454.	1.6	67
225	Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1789-1799.	1.1	66
226	Coronary stents: novel developments. <i>Heart</i> , 2014, 100, 1051-1061.	1.2	65
227	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2014, 177, 448-454.	0.8	65
228	Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2528-2538.	1.1	65
229	Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. <i>European Heart Journal</i> , 2008, 29, 718-725.	1.0	64
230	Impact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 301-310.	1.1	64
231	Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 456-462.	1.0	64
232	Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	64
233	Incidence, predictors and clinical outcomes of residual stenosis after aortic valve-in-valve. <i>Heart</i> , 2018, 104, 828-834.	1.2	64
234	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	1.0	64

#	ARTICLE	IF	CITATIONS
235	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries. JACC: Cardiovascular Interventions, 2016, 9, 1324-1334.	1.1	63
236	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With Durable Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2018, 11, 995-1002.	1.1	63
237	Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%. JAMA Cardiology, 2019, 4, 64.	3.0	63
238	The Impact of Anemia on Long-Term Clinical Outcome in Patients Undergoing Revascularization With the Unrestricted Use of Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2012, 5, 202-210.	1.4	61
239	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. American Heart Journal, 2016, 175, 56-65.	1.2	61
240	Radiation Exposure and Vascular Access in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	1.2	61
241	Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4). JACC: Cardiovascular Imaging, 2019, 12, 1518-1528.	2.3	61
242	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. JACC: Cardiovascular Interventions, 2019, 12, 2173-2182.	1.1	60
243	Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2020, 75, 3020-3030.	1.2	60
244	Patent Foramen Ovale and Cryptogenic Stroke: To Close or Not to Close? Closure: What Else!. Circulation, 2008, 118, 1989-1997.	1.6	59
245	Thrombo-embolic prevention after transcatheter aortic valve implantation. European Heart Journal, 2017, 38, 3341-3350.	1.0	59
246	Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 204-212.	1.0	59
247	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. JACC: Cardiovascular Interventions, 2019, 12, 433-443.	1.1	59
248	Temporal trends in adoption and outcomes of transcatheter aortic valve implantation: a Swiss TAVI Registry analysis. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 242-251.	1.8	59
249	The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 593-601.	1.1	58
250	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
251	Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. EuroIntervention, 2014, 10, 982-989.	1.4	57
252	Effect of endurance training on coronary artery size and function in healthy men: an invasive followup study. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2216-H2223.	1.5	56

#	ARTICLE	IF	CITATIONS
253	Future treatment strategies in ST-segment elevation myocardial infarction. <i>Lancet, The</i> , 2013, 382, 644-657.	6.3	56
254	Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 355-364.	1.4	56
255	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2017, 167, 17.	2.0	56
256	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1870-1883.	1.1	56
257	Long-Term Vascular Healing in Response to Sirolimus- and Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 946-957.	1.1	55
258	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 737-745.	1.1	54
259	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 2211-2217.	1.0	54
260	Expanding Indications of Transcatheter Heart Valve Interventions. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1777-1796.	1.1	53
261	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. <i>American Heart Journal</i> , 2016, 174, 95-102.	1.2	53
262	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019, 209, 97-105.	1.2	53
263	Fluoroscopic Anatomy of Left-Sided Heart Structures for Transcatheter Interventions. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 947-957.	1.1	52
264	Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. <i>European Heart Journal</i> , 2017, 38, 1069-1080.	1.0	52
265	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. <i>JAMA Cardiology</i> , 2021, 6, 410.	3.0	52
266	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	1.1	51
267	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51
268	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	1.2	51
269	Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock. <i>Current Opinion in Critical Care</i> , 2007, 13, 521-527.	1.6	50
270	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 464-470.	1.1	50

#	ARTICLE	IF	CITATIONS
271	Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. <i>Journal of the American Heart Association</i> , 2016, 5, e003255.	1.6	50
272	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
273	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010, 105, 475-479.	0.7	49
274	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	1.1	49
275	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
276	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	1.4	49
277	In vitro evaluation of implantation depth in valve-in-valve using different transcatheter heart valves. <i>EuroIntervention</i> , 2016, 12, 909-917.	1.4	49
278	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 861-870.	1.1	48
279	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. <i>BMJ</i> , The, 2016, 355, i5483.	3.0	48
280	Primary Results of the EVOLVE Short DAPT Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010144.	1.4	48
281	Clinical Outcome of High-Risk Patients with Severe Aortic Stenosis and Reduced Left Ventricular Ejection Fraction Undergoing Medical Treatment or TAVI. <i>PLoS ONE</i> , 2011, 6, e27556.	1.1	47
282	Effect of B-type Natriuretic Peptides on Long-Term Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2015, 116, 1560-1565.	0.7	47
283	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	1.1	47
284	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	1.0	46
285	Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: Comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. <i>American Heart Journal</i> , 2011, 162, 922-931.	1.2	45
286	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>European Heart Journal</i> , 2018, 39, 1591-1601.	1.0	45
287	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	1.4	45
288	Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , 2014, 173, 259-267.	0.8	44

#	ARTICLE	IF	CITATIONS
289	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the <scp>LEADERS</scp> all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E248-60.	0.7	44
290	Evolution of Cognitive Function After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	44
291	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018, 114, 1178-1188.	1.8	44
292	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1438-1447.	1.1	44
293	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1954-1962.	1.1	44
294	Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008152.	1.4	44
295	Diagnosis and Management of Anomalous Coronary Arteries with a Malignant Course. <i>Interventional Cardiology Review</i> , 2019, 14, 83-88.	0.7	44
296	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. <i>BMJ, The</i> , 2016, 354, i4935.	3.0	43
297	Early Detection of Subclinical Myocardial Damage in Chronic Aortic Regurgitation and Strategies for Timely Treatment of Asymptomatic Patients. <i>Circulation</i> , 2018, 137, 184-196.	1.6	43
298	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1576-1586.	1.1	43
299	Feasibility of cardiovascular magnetic resonance to detect oxygenation deficits in patients with multi-vessel coronary artery disease triggered by breathing maneuvers. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 31.	1.6	43
300	Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. <i>EuroIntervention</i> , 2013, 8, 1061-1071.	1.4	43
301	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1999-2009.	1.1	42
302	Hemodynamic Relevance of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva-In Search of the Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 591326.	1.1	42
303	Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2022, 18, 33-42.	1.4	42
304	Post-procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	41
305	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1196-1211.	1.6	41
306	Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1182-1193.	1.1	41

#	ARTICLE	IF	CITATIONS
307	Current Status of Drug-Eluting Stents. <i>Cardiovascular Therapeutics</i> , 2011, 29, 176-189.	1.1	40
308	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 341-349.	1.1	40
309	2-Year Outcomes After Transcatheterâ€Mitrval Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1671-1678.	1.1	40
310	2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1538-1548.	1.1	40
311	Transcatheter aortic valve implantation: the procedure. <i>Heart</i> , 2012, 98, iv44-iv51.	1.2	39
312	Can Coronary Computed Tomography Angiography Replace Invasive Angiography?. <i>Circulation</i> , 2015, 131, 418-426.	1.6	39
313	Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 704-717.	1.1	39
314	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 206-217.	0.6	39
315	Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3127-3136.	1.2	39
316	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	1.4	39
317	Duration of Dual Antiplatelet Therapy forâ€Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2060-2072.	1.2	39
318	Preinterventional screening of the TAVI patient: how to choose the suitable patient and the best procedure. <i>Clinical Research in Cardiology</i> , 2014, 103, 259-274.	1.5	38
319	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2015, 37, ehv614.	1.0	38
320	Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1657-1666.	1.1	38
321	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1374-1383.	1.1	38
322	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006132.	1.4	38
323	Mitral regurgitation in heart failure: time for a rethink. <i>European Heart Journal</i> , 2019, 40, 2189-2193.	1.0	38
324	Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1503-1514.	1.1	38

#	ARTICLE	IF	CITATIONS
325	Severe aortic stenosis and coronary artery disease. <i>EuroIntervention</i> , 2013, 9, S63-S68.	1.4	38
326	Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?. <i>European Heart Journal</i> , 2022, 43, 2729-2750.	1.0	38
327	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37
328	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. <i>European Journal of Internal Medicine</i> , 2015, 26, 56-62.	1.0	37
329	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , 2016, 118, 1888-1896.	0.7	37
330	Atrial Fibrillation following Device Closure of Patent Foramen Ovale. <i>Cardiology</i> , 2008, 111, 47-50.	0.6	36
331	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. <i>American Heart Journal</i> , 2010, 159, 891-898.e1.	1.2	36
332	Stroke. <i>Circulation</i> , 2012, 126, 2921-2924.	1.6	36
333	Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1872-1879.	1.1	36
334	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018, 5, e000695.	0.9	36
335	Nonejecting Hearts on Femoral Veno-Arterial Extracorporeal Membrane Oxygenation: Aortic Root Blood Stasis and Thrombus Formation—A Case Series and Review of the Literature. <i>Critical Care Medicine</i> , 2018, 46, e459-e464.	0.4	36
336	Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 398-404.	0.5	36
337	Time-Dependent Myocardial Necrosis in Patients With ST-Segment Elevation Myocardial Infarction Without Angiographic Collateral Flow Visualized by Cardiac Magnetic Resonance Imaging: Results From the Multicenter STEMI-SCAR Project. <i>Journal of the American Heart Association</i> , 2019, 8, e012429.	1.6	36
338	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 820-830.	1.1	36
339	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
340	The three year follow-up of the randomised ðœall-comersâ€•trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). <i>EuroIntervention</i> , 2011, 7, 789-795.	1.4	36
341	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. <i>Circulation</i> , 2018, 138, 646-648.	1.6	35
342	Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008537.	1.4	35

#	ARTICLE	IF	CITATIONS
343	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2187-2199.	1.2	35
344	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
345	Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 490-495.	0.7	34
346	First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 147-156.	1.1	34
347	New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>Heart</i> , 2018, 104, 1208-1215.	1.2	34
348	Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 770.	0.7	34
349	Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial. <i>American Heart Journal</i> , 2020, 223, 72-80.	1.2	34
350	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2408-2421.	1.2	34
351	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014, 100, 1750-1756.	1.2	33
352	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 639-648.	1.1	33
353	Management of ST-elevation myocardial infarction according to European and American guidelines. <i>EuroIntervention</i> , 2014, 10, T23-T31.	1.4	33
354	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 887-895.	1.1	32
355	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 27 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
356	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
357	Transfemoral Approach for Coronary Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2269-2279.	1.1	32
358	Predicting Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
359	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1231-1242.	1.2	32
360	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006752.	1.4	32

#	ARTICLE	IF	CITATIONS
361	The hospital results and 1-year outcomes of transcatheter aortic valve-in-valve procedures and transcatheter aortic valve implantations in the native valves: the results from the Swiss-TAVI Registry. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 55-63.	0.6	32
362	Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2019, 40, 1909-1919.	1.0	32
363	Utility of Multimodality Intravascular Imaging and the Local Hemodynamic Forces to Predict Atherosclerotic Disease Progression. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1021-1032.	2.3	32
364	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 554-564.	1.1	32
365	Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. <i>European Journal of Heart Failure</i> , 2022, 24, 887-898.	2.9	32
366	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. <i>Heart</i> , 2013, 99, 626-633.	1.2	31
367	Short Versus Long Duration of DAPT After DES Implantation: A Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2014, 64, 953-954.	1.2	31
368	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
369	Current Use of Intracoronary Imaging in Interventional Practice – Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>Circulation Journal</i> , 2018, 82, 1360-1368.	0.7	31
370	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	1.2	31
371	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2572-2584.	1.2	31
372	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1688-1703.	1.1	31
373	Percutaneous Closure of Patent Foramen Ovale in Symptomatic Patients. <i>Journal of Interventional Cardiology</i> , 2001, 14, 203-210.	0.5	30
374	Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). <i>American Heart Journal</i> , 2019, 211, 45-53.	1.2	30
375	Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. <i>Swiss Medical Weekly</i> , 2008, 138, 567-72.	0.8	30
376	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
377	Sirolimus-eluting coronary stents in small vessels. <i>American Heart Journal</i> , 2006, 151, 1019.e1-1019.e7.	1.2	29
378	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 5162-5166.	0.8	29

#	ARTICLE	IF	CITATIONS
379	Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	29
380	“One-Stop Shop”. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1487-1495.	1.1	29
381	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017, 184, 71-80.	1.2	29
382	Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. <i>Expert Review of Medical Devices</i> , 2017, 14, 773-788.	1.4	29
383	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1559-1571.	1.1	29
384	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. <i>European Heart Journal</i> , 2018, 39, 3381-3389.	1.0	29
385	Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. <i>European Heart Journal</i> , 2019, 40, 1342-1351.	1.0	29
386	Coronary artery disease in patients undergoing TAVI: why, what, when and how to treat. <i>EuroIntervention</i> , 2014, 10, U69-U75.	1.4	29
387	Impact of local endothelial shear stress on neointima and plaque following stent implantation in patients with ST-elevation myocardial infarction: A subgroup-analysis of the COMFORTABLE AMI “IBIS 4 trial. <i>International Journal of Cardiology</i> , 2015, 186, 178-185.	0.8	28
388	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	1.1	28
389	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 522-532.	0.5	28
390	ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19 acute respiratory distress syndrome. <i>European Heart Journal</i> , 2020, 41, 2134-2134.	1.0	28
391	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 1038-1046.	1.0	28
392	Age-Related Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 952-960.	1.1	28
393	Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. <i>Heart</i> , 2012, 98, 1424-1430.	1.2	27
394	Baseline serum bicarbonate levels independently predict short-term mortality in critically ill patients with ischaemic cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 45-52.	0.4	27
395	Meta-Analysis of Bioprosthetic Valve Thrombosis After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 138, 92-99.	0.7	27
396	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27

#	ARTICLE	IF	CITATIONS
397	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2206-2219.	2.3	27
398	What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?. <i>EuroIntervention</i> , 2017, 12, 1684-1687.	1.4	27
399	Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. <i>EuroIntervention</i> , 2012, 7, 1435-1443.	1.4	27
400	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. <i>EuroIntervention</i> , 2016, 12, e1343-e1354.	1.4	27
401	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 "epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
402	Patent Foramen Ovale May Be Causal for the First Stroke but Unrelated to Subsequent Ischemic Events. <i>Stroke</i> , 2011, 42, 2891-2895.	1.0	26
403	Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. <i>American Heart Journal</i> , 2012, 163, 876-886.e2.	1.2	26
404	Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0137047.	1.1	26
405	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015, 187, 111-115.	0.8	26
406	Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. <i>Heart</i> , 2015, 101, 30-36.	1.2	26
407	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009685.	1.4	26
408	Deleterious Effect of Coronary Brachytherapy on Vasomotor Response to Exercise. <i>Circulation</i> , 2004, 110, 135-140.	1.6	25
409	Comparison of Titanium-Nitride-Oxide-Coated Stents With Zotarolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 672-682.	1.1	25
410	Impact of Mitral Regurgitation on Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001895.	1.4	25
411	Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
412	Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E38-E43.	0.7	25
413	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
414	Fluoroscopic Anatomy of Right-Sided Heart Structures for Transcatheter Interventions. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1614-1625.	1.1	25

#	ARTICLE	IF	CITATIONS
415	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 361-373.	1.1	25
416	Impact of B-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2015, 10, e1-e8.	1.4	25
417	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. <i>EuroIntervention</i> , 2016, 12, 482-489.	1.4	25
418	Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. <i>American Heart Journal</i> , 2013, 166, 83-94.e3.	1.2	24
419	The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. <i>International Journal of Cardiology</i> , 2014, 175, 314-322.	0.8	24
420	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1473-1483.	1.1	24
421	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13117.	1.7	24
422	Association of ECG parameters with late gadolinium enhancement and outcome in patients with clinical suspicion of acute or subacute myocarditis referred for CMR imaging. <i>PLoS ONE</i> , 2020, 15, e0227134.	1.1	24
423	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	1.4	24
424	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 513-526.	1.2	24
425	Technical Approach Determines Inflammatory Response after Surgical and Transcatheter Aortic Valve Replacement. <i>PLoS ONE</i> , 2015, 10, e0143089.	1.1	23
426	Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2015, 4, e002135.	1.6	23
427	Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1780-1789.	1.1	23
428	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017, 243, 150-155.	0.8	23
429	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1665-1675.	1.1	23
430	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
431	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	1.6	23
432	Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 124-129.	0.7	22

#	ARTICLE	IF	CITATIONS
433	Anatomical Eligibility of the Renal Vasculature for Catheter-Based Renal Denervation in Hypertensive Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 187-192.	1.1	22
434	Regression of coronary atherosclerosis: Current evidence and future perspectives. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 150-161.	2.3	22
435	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016, 247, 154-160.	0.4	22
436	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	1.1	22
437	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 205, 110-117.	1.2	22
438	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 758-774.	1.2	22
439	Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 124-139.	2.3	22
440	Mortality, Stroke, and Hospitalization Associated With Deferred vs Expedited Aortic Valve Replacement in Patients Referred for Symptomatic Severe Aortic Stenosis During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2020402.	2.8	22
441	Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 532-541.	1.8	22
442	Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 905-913.	1.1	21
443	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017, 77, 1733-1754.	4.9	21
444	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008024.	1.4	21
445	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. <i>Cardiovascular Diabetology</i> , 2019, 18, 142.	2.7	21
446	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial. <i>EuroIntervention</i> , 2011, 7, 605-613.	1.4	21
447	Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. <i>EuroIntervention</i> , 2014, 9, 1432-1440.	1.4	21
448	Future perspectives in transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2013, 168, 11-18.	0.8	20
449	Expansion of transcatheter aortic valve implantation: new indications and socio-economic considerations. <i>European Heart Journal</i> , 2018, 39, 2643-2645.	1.0	20
450	Design of the randomized, placebo-controlled evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. <i>Clinical Cardiology</i> , 2018, 41, 1513-1520.	0.7	20

#	ARTICLE	IF	CITATIONS
451	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: CardioOncology</i> , 2019, 1, 145-155.	1.7	20
452	Sudden Cardiac Death in Ischemic Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2223-2238.	2.3	20
453	Predictors of Outcomes Following Transcatheter Edge-to-Edge Mitral Valve Repair. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1733-1748.	1.1	20
454	Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 356-365.	0.7	20
455	Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 60.	1.1	20
456	Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2246-2256.	1.1	20
457	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 15, e1605-e1614.	1.4	20
458	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015, 10, 1425-1431.	1.4	20
459	Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. <i>Trials</i> , 2011, 12, 56.	0.7	19
460	Transcatheter aortic valve implantation: prevention and management of complications. <i>Heart</i> , 2012, 98, iv52-iv64.	1.2	19
461	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1621-1630.	1.1	19
462	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
463	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	0.7	19
464	Sirolimus Eluting Stent: A New Era in Interventional Cardiology?. <i>Current Pharmaceutical Design</i> , 2003, 9, 1077-1094.	0.9	19
465	The outcome of bifurcation lesion stenting using a sirolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , 2011, 6, 928-935.	1.4	19
466	Safety of drug-eluting stents. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 316-328.	3.3	18
467	Patent Foramen Ovale Screening by Ear Oximetry in Divers. <i>American Journal of Cardiology</i> , 2013, 111, 286-290.	0.7	18
468	Preprocedural High-Sensitivity Cardiac Troponin T and Clinical Outcomes in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	18

#	ARTICLE	IF	CITATIONS
469	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons. <i>BMJ Open</i> , 2016, 6, e011520.	0.8	18
470	Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1216-1227.	1.1	18
471	Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E73-E84.	0.7	18
472	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017, 120, 2025-2030.	0.7	18
473	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	0.8	18
474	Valvular and Nonvalvular Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2124-2133.	1.1	18
475	Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at Tj ETQq1 1 0,784314 rgBT /Overl...)	0.7	18
476	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-specified Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e015560.	1.6	18
477	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. <i>EuroIntervention</i> , 2020, 16, 627-633.	1.4	18
478	Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. <i>Europace</i> , 2022, 24, 1441-1450.	0.7	18
479	Clinical use of temporary percutaneous left ventricular assist devices. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 304-313.	0.7	17
480	Trombosis muy tardía con nuevos stents farmacoactivos: ¿ha dejado de ser un asunto relevante?. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 595-598.	0.6	17
481	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020, 223, 44-47.	1.2	17
482	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
483	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. <i>American Heart Journal</i> , 2021, 238, 33-44.	1.2	17
484	Transcatheter aortic valve implantation and cerebrovascular accidents. <i>EuroIntervention</i> , 2012, 8, Q60-Q69.	1.4	17
485	Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011302.	1.4	17
486	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014, 168, 256-261.	1.2	16

#	ARTICLE	IF	CITATIONS
487	Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 118, 345-352.	0.7	16
488	Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. <i>International Journal of Cardiology</i> , 2018, 272, 7-12.	0.8	16
489	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1273-1284.	0.8	16
490	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
491	The PASCAL Device—Early Experience with a Leaflet Approximation Device: What Are the Benefits/Limitations Compared with the MitraClip?. <i>Current Cardiology Reports</i> , 2020, 22, 74.	1.3	16
492	Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 567-579.	1.1	16
493	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2020, 225, 60-68.	1.2	16
494	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021, 143, 2143-2154.	1.6	16
495	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
496	Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. <i>EuroIntervention</i> , 2021, 17, 848-855.	1.4	16
497	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2022, 18, e377-e388.	1.4	16
498	Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 145-154.	1.1	15
499	Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. <i>Heart</i> , 2015, 101, 271-278.	1.2	15
500	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 277, 219-226.	0.4	15
501	Impact of Bleeding and Myocardial Infarction on Mortality in All-Coroner Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	1.4	15
502	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). <i>American Journal of Cardiology</i> , 2020, 125, 1369-1377.	0.7	15
503	Quantitative Flow Ratio to Predict Nontarget Vessel-Related Events at 5 Years in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Angiography-Guided Revascularization. <i>Journal of the American Heart Association</i> , 2021, 10, e019052.	1.6	15
504	Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score-matched cohorts comparison. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 2037-2046.e4.	0.4	15

#	ARTICLE	IF	CITATIONS
505	Health utility indexes in patients with acute coronary syndromes. <i>Open Heart</i> , 2016, 3, e000419.	0.9	14
506	Developing drugs for use before, during and soon after percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 803-818.	0.9	14
507	Evolving Indications for Transcatheter Aortic Valve Interventions. <i>Current Cardiology Reports</i> , 2017, 19, 107.	1.3	14
508	Percutaneous Mitral Edge-to-Edge Repair: State of the Art and a Glimpse to the Future. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 122.	1.1	14
509	Implications of the local haemodynamic forces on the phenotype of coronary plaques. <i>Heart</i> , 2019, 105, 1078-1086.	1.2	14
510	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
511	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
512	Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 981-991.	1.1	14
513	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. <i>American Heart Journal</i> , 2021, 235, 140-148.	1.2	14
514	Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2021, 10, e019815.	1.6	14
515	Incidence and Outcomes of Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2021, 10, e020368.	1.6	14
516	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
517	Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. <i>EuroIntervention</i> , 2009, 5, 310-317.	1.4	14
518	Percutaneous ventricular assist devices for cardiogenic shock. <i>Current Heart Failure Reports</i> , 2008, 5, 163-169.	1.3	13
519	Implications of Bicuspid Aortic Valves for Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 204-206.	1.4	13
520	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1867-1877.	1.1	13
521	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	1.0	13
522	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	1.4	13

#	ARTICLE	IF	CITATIONS
523	Current Generation Balloon-Expandable Transcatheter Valve Positioning Strategies During Aortic Valve-in-Valve Procedures and Clinical Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1606-1617.	1.1	13
524	Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. <i>International Journal of Cardiology</i> , 2019, 290, 45-51.	0.8	13
525	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE III and BIOFLOW II trials. <i>International Journal of Cardiology</i> , 2020, 300, 60-65.	0.8	13
526	How to shape the future of cardiology and cardiac surgery?. <i>European Heart Journal</i> , 2020, 41, 3693-3701.	1.0	13
527	Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1815-1826.	1.1	13
528	Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 249-258.	1.8	13
529	Anatomical and Technical Predictors of Three-Dimensional Mitral Valve Area Reduction After Transcatheter Edge-To-Edge Repair. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 96-104.	1.2	13
530	Additive Effect of Anemia and Renal Impairment on Long-Term Outcome after Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2014, 9, e114846.	1.1	13
531	Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial. <i>EuroIntervention</i> , 2020, 16, 833-841.	1.4	13
532	Thrombus formation in the left ventricle after large myocardial infarction – assessment with cardiac magnetic resonance imaging. <i>Swiss Medical Weekly</i> , 2015, 145, w14122.	0.8	13
533	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , 2021, 17, e971-e980.	1.4	13
534	Bioresorbable Scaffolds Versus Metallic Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2310-2314.	1.2	12
535	Nonbacterial thrombotic endocarditis presenting as intracerebral hemorrhage. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 922-924.	1.0	12
536	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
537	Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients. <i>Current Opinion in Cardiology</i> , 2017, 32, 117-122.	0.8	12
538	Long-term clinical outcomes of Amplatzer cardiac plug versus Amulet occluders for left atrial appendage closure. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E324-E331.	0.7	12
539	Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized research in women all) <i>TJ ETQq1 1 0.784314 rgb1 /Overl</i>	1.2	12
540	Differential Effects of Newer-Generation Ultrathin-Strut Versus Thicker-Strut Drug-Eluting Stents in Chronic and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2461-2473.	1.1	12

#	ARTICLE	IF	CITATIONS
541	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
542	Acute Coronary Syndromes. <i>Herz</i> , 2008, 33, 25-37.	0.4	11
543	Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	11
544	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 744-754.	1.5	11
545	Barriers to cardiovascular device innovation in Europe. <i>European Heart Journal</i> , 2016, 37, 140-144.	1.0	11
546	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. <i>International Journal of Cardiology</i> , 2018, 260, 42-46.	0.8	11
547	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
548	From bare metal to barely anything: an update on coronary stenting. <i>Heart</i> , 2018, 104, 533-540.	1.2	11
549	Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 314-322.	0.5	11
550	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	1.0	11
551	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019, 124, 1020-1026.	0.7	11
552	Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study. <i>Clinical Research in Cardiology</i> , 2020, 109, 444-453.	1.5	11
553	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006660.	0.9	11
554	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009189.	1.4	11
555	Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008657.	1.4	11
556	Permanent pacemaker implantation late after transcatheter aortic valve implantation. <i>Heart Rhythm</i> , 2021, 18, 2033-2039.	0.3	11
557	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018, 250, 73-79.	0.8	11
558	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. <i>EuroIntervention</i> , 2018, 14, 692-699.	1.4	11

#	ARTICLE	IF	CITATIONS
559	Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial. <i>EuroIntervention</i> , 2016, 12, e595-e604.	1.4	11
560	Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 353-364.	1.1	11
561	Reproducibility of 4D cardiac computed tomography feature tracking myocardial strain and comparison against speckle-tracking echocardiography in patients with severe aortic stenosis. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 309-318.	0.7	11
562	Clinical relevance of coronary angiography at the time of percutaneous closure of a patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 641-645.	0.7	10
563	Drug-eluting stent technology: progress beyond the polymer. <i>European Heart Journal</i> , 2014, 35, 1991-1995.	1.0	10
564	Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. <i>Open Heart</i> , 2014, 1, e000014.	0.9	10
565	Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2017, 119, 501-507.	0.7	10
566	Long-term outcomes after acute myocardial infarction in countries with different socioeconomic environments: an international prospective cohort study. <i>BMJ Open</i> , 2017, 7, e012715.	0.8	10
567	Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	10
568	Biodegradable vs. permanent polymer drug-eluting stents: the need for a new nomenclature to classify drug-eluting stent technology. <i>European Heart Journal</i> , 2019, 40, 2616-2619.	1.0	10
569	Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3610-3620.	1.4	10
570	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, .	1.4	10
571	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006581.	0.9	10
572	Impella versus extracorporeal life support in cardiogenic shock: a propensity score adjusted analysis. <i>ESC Heart Failure</i> , 2021, 8, 953-961.	1.4	10
573	The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents. <i>PLoS ONE</i> , 2014, 9, e106450.	1.1	10
574	Evaluation and treatment of abnormalities of the interatrial septum. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 94-103.	0.7	9
575	Sirolimus versus paclitaxel coronary stents in clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 5-12.	0.7	9
576	Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: Methodology and external validation. <i>Contemporary Clinical Trials</i> , 2013, 34, 53-59.	0.8	9

#	ARTICLE	IF	CITATIONS
577	Dual Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003587.	1.4	9
578	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-11.	0.5	9
579	1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 673-680.	1.1	9
580	Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>EuroIntervention</i> , 2021, 16, 1177-1186.	1.4	9
581	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
582	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	0.4	9
583	First Clinical Results With a New Mechanical Connector for Distal Coronary Artery Anastomoses in CABG. <i>Circulation</i> , 2002, 106, .	1.6	9
584	Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. <i>EuroIntervention</i> , 2015, 11, 171-179.	1.4	9
585	Introducing a new EAPCI programme: the Valve for Life initiative. <i>EuroIntervention</i> , 2016, 11, 977-979.	1.4	9
586	Mechanical compression of coronary artery stents: Potential hazard for patients undergoing cardiopulmonary resuscitation. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 51, 464-467.	0.7	8
587	Very Late Stent Thrombosis With Newer Drug-Eluting Stents: No Longer an Issue?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 595-598.	0.4	8
588	Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. <i>Heart</i> , 2015, 101, 50-57.	1.2	8
589	Aspiration Thrombectomy for Treatment of ST-segment Elevation Myocardial Infarction: a Meta-analysis of 26 Randomized Trials in 11 943 Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 746-752.	0.4	8
590	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1667-1676.	1.1	8
591	Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. <i>American Heart Journal</i> , 2017, 189, 128-136.	1.2	8
592	The Conundrum of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	8
593	Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Clinical Research in Cardiology</i> , 2018, 107, 338-346.	1.5	8
594	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. <i>International Journal of Cardiology</i> , 2019, 287, 59-61.	0.8	8

#	ARTICLE	IF	CITATIONS
595	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 618-628.	1.1	8
596	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 860.	1.0	8
597	Impact of effective regurgitant orifice area on outcome of secondary mitral regurgitation transcatheter repair. <i>Clinical Research in Cardiology</i> , 2021, 110, 732-739.	1.5	8
598	One-Year Outcomes of a Randomized Trial Comparing a Self-Expanding With a Balloon-Expandable Transcatheter Aortic Valve. <i>Circulation</i> , 2021, 143, 1267-1269.	1.6	8
599	Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. <i>IJC Heart and Vasculature</i> , 2021, 33, 100768.	0.6	8
600	Efficacy and safety of ethanol infusion into the vein of Marshall for mitral isthmus ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1610-1619.	0.8	8
601	Deep learning-based prediction of early cerebrovascular events after transcatheter aortic valve replacement. <i>Scientific Reports</i> , 2021, 11, 18754.	1.6	8
602	Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. <i>EuroIntervention</i> , 2010, 6, 467-474.	1.4	8
603	Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. <i>EuroIntervention</i> , 2014, 10, U61-U68.	1.4	8
604	Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Heart Journal</i> , 2022, 244, 94-106.	1.2	8
605	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	1.2	8
606	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. <i>Clinical Research in Cardiology</i> , 2022, 111, 795-805.	1.5	8
607	Functional Status After Transcatheter and Surgical Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 728-738.	1.1	8
608	Interventional PFO closure: What we see is but the tip of the iceberg. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 50, 199-201.	0.7	7
609	Anatomical Suitability for Transcatheter Aortic Valve Implantation With Complementary Roles for 2 Rivals. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 867-869.	1.1	7
610	Neointimal hyperplasia as reason for stent failures beyond 5 years after drug-eluting stent implantation. <i>European Heart Journal</i> , 2014, 35, 1980-1980.	1.0	7
611	Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 981-983.	1.1	7
612	Joint EACVI HIT/EAPCI young survey/ESC CoT survey: training and education for "multimodality imaging in structural interventions": the rise of a new sub-specialty?. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1432-1433.	0.5	7

#	ARTICLE	IF	CITATIONS
613	1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 727-738.	1.2	7
614	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	7
615	Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: Evolution of treatment effect during follow-up. <i>International Journal of Cardiology</i> , 2018, 255, 29-31.	0.8	7
616	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. <i>Circulation</i> , 2019, 140, 1960-1963.	1.6	7
617	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	0.4	7
618	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	1.4	7
619	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	1.4	7
620	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 893-901.	0.4	7
621	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a Multicenter Randomized Open-label Trial in Patients with ST-elevation Myocardial Infarction Referred for Primary Percutaneous Intervention (FABOLUS FASTER) Trial: Design and Rationale. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 110-119.	1.1	7
622	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 235-242.	0.8	7
623	Evolution of Basic Activities of Daily Living Function in Older Patients One Year After Transcatheter Aortic Valve Implantation. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 500-505.	1.3	7
624	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
625	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 649-657.	1.5	7
626	Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E768-E779.	0.7	7
627	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 930-940.	1.1	7
628	Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction. <i>JAMA Cardiology</i> , 2021, 6, 1171.	3.0	7
629	HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. <i>Minerva Medica</i> , 2020, 111, 203-212.	0.3	7
630	Vascular restoration therapy: what should the clinical and angiographic measures for success be?. <i>EuroIntervention</i> , 2009, 5, F49-F53.	1.4	7

#	ARTICLE	IF	CITATIONS
631	Clinical outcomes and cardiac rehabilitation in underrepresented groups after percutaneous coronary intervention: an observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1093-1103.	0.8	7
632	The Drug-Eluting Stent Saga. <i>Circulation</i> , 2009, 119, 653-656.	1.6	6
633	Lack of Blood Pressure-lowering Effect of Renal Denervation in a Drug-naïve Patient with Pronounced Arterial Stiffening. <i>American Journal of Medicine</i> , 2014, 127, e3-e4.	0.6	6
634	Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1064-1074.	1.1	6
635	Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1335-1338.	1.2	6
636	Newer-Generation Devices for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 373-375.	1.1	6
637	A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. <i>PLoS ONE</i> , 2017, 12, e0182632.	1.1	6
638	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	0.8	6
639	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
640	PASCAL. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1379-1381.	1.1	6
641	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	1.1	6
642	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
643	Randomized Comparison of Optical Coherence Tomography Versus Angiography to Guide Bioresorbable Vascular Scaffold Implantation: The OPTICO BVS Study. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1244-1250.	0.3	6
644	Predictive value of the QFR in detecting vulnerable plaques in non-flow limiting lesions: a combined analysis of the PROSPECT and IBIS-4 study. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 993-1002.	0.7	6
645	Optimal Timing of Invasive Coronary Angiography following NSTEMI. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	0.5	6
646	Rivaroxaban after transcatheter aortic valve replacement: the GALILEO trial. <i>Cardiovascular Research</i> , 2020, 116, e39-e41.	1.8	6
647	Predicting 2-year all-cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	0.7	6
648	Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 756-764.	0.7	6

#	ARTICLE	IF	CITATIONS
649	Impact of Intracoronary Optical Coherence Tomography in Routine Clinical Practice: A Contemporary Cohort Study. <i>Cardiovascular Revascularization Medicine</i> , 2022, 38, 96-103.	0.3	6
650	Final 3-year clinical outcomes following transcatheter aortic valve implantation with a supra-annular self-expanding repositionable valve in a real-world setting: Results from the multicenter FORWARD study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	6
651	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020, 226, 4-12.	1.2	6
652	The Self-Expanding Symetis Acurate Does Not Increase Cerebral Microembolic Load When Compared to the Balloon-Expandable Edwards Sapien Prosthesis: A Transcranial Doppler Study in Patients Undergoing Transapical Aortic Valve Implantation. <i>PLoS ONE</i> , 2014, 9, e108191.	1.1	6
653	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 16, 634-644.	1.4	6
654	Predictors of Prosthetic Valve Regurgitation After Transcatheter Aortic Valve Implantation With ACURATE neo in the SCOPE I Trial. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 367-369.	2.3	6
655	Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 178.	0.7	6
656	Percutaneous left ventricular assist devices during cardiogenic shock and high-risk percutaneous coronary interventions. <i>Current Cardiology Reports</i> , 2009, 11, 369-376.	1.3	5
657	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. <i>Europace</i> , 2015, 17, 1319-1322.	0.7	5
658	Misconceptions and Facts About Aortic Stenosis. <i>American Journal of Medicine</i> , 2017, 130, 398-402.	0.6	5
659	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 480-486.	0.3	5
660	Sheathless Transcaval Transcatheter Aortic Valve Implantation Through an Abdominal Aortic Graft. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1688.e17-1688.e19.	0.8	5
661	Case report of simultaneous transcatheter mitral valve-in-valve implantation and percutaneous closure of two paravalvular leaks. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz123.	0.3	5
662	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	0.7	5
663	Application of the MADS classification system in a "omega mammoth" stent trial: Feasibility and preliminary clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 57-63.	0.7	5
664	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	0.8	5
665	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	0.7	5
666	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 3-10.	0.3	5

#	ARTICLE	IF	CITATIONS
667	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 445-452.	0.4	5
668	Acute coronary syndromes in young patients: Phenotypes, causes and clinical outcomes following percutaneous coronary interventions.. <i>International Journal of Cardiology</i> , 2022, 350, 1-8.	0.8	5
669	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
670	Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 317-334.	2.2	4
671	Effect of Right Ventricular Function and Tricuspid Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	4
672	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1016-1026.	0.7	4
673	Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 204, 34-42.	1.2	4
674	Surgical Transatrial Implantation of Transcatheter Heart Valves in Severe Mitral Annular Calcification. <i>Interventional Cardiology Clinics</i> , 2019, 8, 313-319.	0.2	4
675	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	0.8	4
676	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.4	4
677	Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E919-E928.	0.7	4
678	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021, 324, 30-37.	0.8	4
679	True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 366-377.	1.8	4
680	Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 873-878.	1.1	4
681	Hemolysis After Transcatheter Mitral Valve Implantation Resolved by Valve Retensioning. <i>JACC: Case Reports</i> , 2021, 3, 864-870.	0.3	4
682	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1170-1179.	0.4	4
683	A vote taking place on 2 December 2015 (EUCOMED) that will definitely influence our profession and continuing medical education. <i>EuroIntervention</i> , 2015, 11, 847-849.	1.4	4
684	External validity of a contemporaneous primary percutaneous coronary intervention trial in patients with acute ST-elevation myocardial infarction: insights from a single-centre investigation. <i>EuroIntervention</i> , 2016, 12, 1135-1143.	1.4	4

#	ARTICLE	IF	CITATIONS
685	Interventional cardiology's golden age of contributions to evidence-based medicine. EuroIntervention, 2019, 15, 31-34.	1.4	4
686	Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Medical Weekly, 2016, 146, w14333.	0.8	4
687	Retrograde Retrieval of a Novel Large Mitral Clip After Embolization Into the Left Ventricle. JACC: Case Reports, 2021, 3, 1561-1568.	0.3	4
688	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e018828.	1.6	4
689	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT Heart Association, 2021, 10, e020488.	1.6	4
690	Clinical outcomes following transcatheter aortic valve implantation in patients with porcelain aorta. Journal of Cardiovascular Computed Tomography, 2022, 16, 215-221.	0.7	4
691	Amplatzer left atrial appendage closure: Single versus combined procedures. Catheterization and Cardiovascular Interventions, 2021, 97, E973-E981.	0.7	4
692	Electrosurgical Laceration and Stabilization of MitraClip Followed by Valve Implantation for latrogenic Mitral Stenosis. JACC: Cardiovascular Interventions, 2022, 15, 110-112.	1.1	4
693	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	1.6	4
694	Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 496-509.	1.8	4
695	Response by Lakireddy et al to Letters Regarding Article, "Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial". Circulation, 2022, 145, e850-e851.	1.6	4
696	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	0.7	4
697	Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation. JAMA Network Open, 2022, 5, e2220689.	2.8	4
698	Response To Letter Regarding Article, "Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification". Circulation: Cardiovascular Interventions, 2015, 8, e003064.	1.4	3
699	Myocardial revascularization in patients with left main or multivessel coronary artery disease at high surgical risk: conventional wisdom versus risk prediction model. European Journal of Cardio-thoracic Surgery, 2017, 51, 949-951.	0.6	3
700	Geographical differences in the ratio of percutaneous and surgical myocardial revascularization procedures in the treatment of coronary artery disease. European Journal of Cardio-thoracic Surgery, 2017, 52, 454-455.	0.6	3
701	Dyspnoea in the GLOBAL LEADERS trial " Authors' reply. Lancet, The, 2019, 393, 2393-2394.	6.3	3
702	Impact of valvular resistance on aortic regurgitation after transcatheter aortic valve replacement according to the type of prosthesis. Clinical Research in Cardiology, 2019, 108, 1343-1353.	1.5	3

#	ARTICLE	IF	CITATIONS
703	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	1.5	3
704	Evaluation of Cumulative Meta-analysis of Rare Events as a Tool for Clinical Trials Safety Monitoring. <i>JAMA Network Open</i> , 2020, 3, e2015031.	2.8	3
705	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	3
706	Deferred versus Expedited Aortic Valve Replacement in Patients with Symptomatic Severe Aortic Stenosis During the SARS-CoV-2 Pandemic (AS DEFER): A Research Letter. <i>Global Heart</i> , 2021, 16, 32.	0.9	3
707	Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E213-E221.	0.7	3
708	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 547-556.	1.4	3
709	Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2839-2847.	0.7	3
710	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 583-592.	0.7	3
711	Interventional treatment of mitral valve regurgitation: an alternative to surgery?. <i>Swiss Medical Weekly</i> , 2019, 149, w20023.	0.8	3
712	Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. <i>PLoS ONE</i> , 2022, 17, e0263180.	1.1	3
713	Long-term outcomes of new-onset conduction abnormalities following transcatheter aortic valve implantation. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 214-224.	0.7	3
714	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. <i>JAMA Cardiology</i> , 2022, 7, 682.	3.0	3
715	Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1488-1500.	0.8	3
716	Coronary Stent Choice in Patients with Acute Myocardial Infarction. <i>Current Cardiology Reports</i> , 2012, 14, 477-485.	1.3	2
717	Stent performance: never too late to sort it out. <i>Lancet, The</i> , 2014, 383, 2024-2026.	6.3	2
718	Mitigating the Risk of Early Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2521-2524.	1.2	2
719	Silent myocardial infarction and stroke: findings of multimodality imaging. <i>European Heart Journal</i> , 2015, 36, 949-949.	1.0	2
720	Prognostications of Fibrillations. <i>Stroke</i> , 2015, 46, 1155-1157.	1.0	2

#	ARTICLE	IF	CITATIONS
721	Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 118, 1798-1804.	0.7	2
722	Myocardial Revascularization for Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1010-1013.	1.2	2
723	Histopathological thrombus analysis in patients with stent thrombosis: what are the missing pieces in the puzzle?. <i>European Heart Journal</i> , 2016, 37, 1550.2-1552.	1.0	2
724	Pitfalls in TAMVI: experience with the repositionable Lotus [®] Valve System. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 47.	0.4	2
725	Sealing the Achilles Heel of Transcatheter Aortic Valve Replacement?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 169-171.	1.1	2
726	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 143-150.	0.3	2
727	Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography. <i>PLoS ONE</i> , 2018, 13, e0202950.	1.1	2
728	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019, 277, 60-65.	0.8	2
729	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	0.8	2
730	The relationship between baseline diastolic dysfunction and postimplantation invasive hemodynamics with transcatheter aortic valve replacement. <i>Clinical Cardiology</i> , 2020, 43, 1428-1434.	0.7	2
731	Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E1002-E1010.	0.7	2
732	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 140, 95-102.	0.7	2
733	Systemic Corticosteroid Exposure and Atrioventricular Conductance Delays After Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 1-6.	0.3	2
734	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. <i>International Journal of Cardiology</i> , 2021, 334, 37-41.	0.8	2
735	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1354-1364.	0.5	2
736	Left atrial appendage closure for prevention of cardioembolic events. <i>Swiss Medical Weekly</i> , 2016, 146, w14298.	0.8	2
737	Time for science to catch up with clinical practice?. <i>Journal of Thoracic Disease</i> , 2015, 7, E603-6.	0.6	2
738	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e023129.	1.6	2

#	ARTICLE	IF	CITATIONS
739	Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. , 2022, 1, 100004.		2
740	Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. Cardiovascular Revascularization Medicine, 2022, 42, 55-61.	0.3	2
741	Clinical benefit of left atrial appendage closure in octogenarians.. Journal of Geriatric Cardiology, 2021, 18, 886-896.	0.2	2
742	Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	2
743	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	1.4	2
744	Head-to-Head and Extrapolated Comparisons of Different Drug-Eluting Stents: Differences in Late Loss, Restenosis, and Clinical Outcomes. Journal of Interventional Cardiology, 2009, 22, .	0.5	1
745	Stents liberadores de paclitaxel en el infarto agudo de miocardio con elevaci3n del segmento ST. Revista Espanola De Cardiologia, 2014, 67, 974-979.	0.6	1
746	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. Postgraduate Medical Journal, 2015, 91, 284-290.	0.9	1
747	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	1.0	1
748	Reply. Journal of the American College of Cardiology, 2016, 67, 1260.	1.2	1
749	Long-Term Assessment of Bioresorbable Coronary Scaffolds. Journal of the American College of Cardiology, 2018, 71, 1894-1896.	1.2	1
750	Biodegradable-polymer stents versus durable-polymer stents â€“ Authors' reply. Lancet, The, 2019, 393, 1933.	6.3	1
751	Two-year outcomes of the MITRAâ€“FR trial: towards an integrated approach in the evaluation of patients with secondary mitral regurgitation. European Journal of Heart Failure, 2019, 21, 1628-1631.	2.9	1
752	Electrocardiographic predictors of mortality in patients after percutaneous coronary interventions â€“ a nested caseâ€“control study. Acta Cardiologica, 2019, 74, 341-349.	0.3	1
753	Drug-Eluting Stent Choice in Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2020, 13, 112-115.	1.1	1
754	ESC Committee for Practice Guidelines: providing knowledge to everyday clinical practice. Cardiovascular Research, 2020, 116, e146-e148.	1.8	1
755	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.4	1
756	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. Expert Review of Medical Devices, 2021, 18, 261-272.	1.4	1

#	ARTICLE	IF	CITATIONS
757	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	0.7	1
758	Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI: a post hoc analysis of the randomized GLOBAL LEADERS trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 756-773.	0.4	1
759	Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair. Catheterization and Cardiovascular Interventions, 2021, 98, 1404-1412.	0.7	1
760	Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR): A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial. Circulation: Cardiovascular Interventions, 2021, 14, e011074.	1.4	1
761	Regulation of coronary stents – physicians as stakeholders. EuroIntervention, 2017, 12, 1679-1680.	1.4	1
762	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	1.6	1
763	Clinical outcomes in high-risk patients with a severe aortic stenosis: a seven-year follow-up analysis. Swiss Medical Weekly, 2019, 149, w20013.	0.8	1
764	Valve-in-Valve Transcatheter Aortic Valve Replacement for the Treatment of Paravalvular Leak Due to Ring Dehiscence. JACC: Cardiovascular Interventions, 2021, 14, 2746-2746.	1.1	1
765	Cardiovascular outcomes in patients with left atrial enlargement undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2022, , .	0.7	1
766	Sustained Ventricular Arrhythmias in Patients Receiving Thrombolytic Therapy. Circulation, 2000, 101, E237-8.	1.6	0
767	Percutaneous closure of patent foramen ovale, atrial septal defects and the left atrial appendage. , 2008, , 449-468.		0
768	Coronary revascularisation in patients with diabetes: a chance to be better. Evidence-Based Medicine, 2013, 18, e59-e59.	0.6	0
769	Paclitaxel-eluting Stents in ST-segment Elevation Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2014, 67, 974-979.	0.4	0
770	Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. Heart, 2014, 100, A38.2-A39.	1.2	0
771	Response to Letter Regarding Article, "Prognostications of Fibrillations" Stroke, 2015, 46, e191.	1.0	0
772	Reply. Journal of the American College of Cardiology, 2015, 65, 313.	1.2	0
773	Reply. Journal of the American College of Cardiology, 2015, 65, 223.	1.2	0
774	Surgical or percutaneous revascularization for isolated left anterior descending stenoses: are we in the same boat?. European Journal of Cardio-thoracic Surgery, 2015, 47, 406-407.	0.6	0

#	ARTICLE	IF	CITATIONS
775	Reply. Journal of the American College of Cardiology, 2016, 67, 2704.	1.2	0
776	Thrombectomy in Primary Angioplasty: Do the Latest Large Studies Address the Doubts About Its Usefulness? Response. Revista Espanola De Cardiología (English Ed), 2016, 69, 231.	0.4	0
777	Trombectomía en angioplastia primaria: ¿aclaran los últimos grandes estudios las dudas sobre su utilidad? Respuesta. Revista Espanola De Cardiología, 2016, 69, 231.	0.6	0
778	Treating nonischaemic stable CAD lesionsâ€”safe to DEFER?. Nature Reviews Cardiology, 2016, 13, 7-8.	6.1	0
779	No significant gender difference in hospitalizations for acute coronary syndrome in Switzerland over the time period of 2001 to 2010. International Journal of Cardiology, 2017, 243, 59-64.	0.8	0
780	Bioresorbable scaffolds: in search of event-free dissolution. Lancet, The, 2017, 390, 720-722.	6.3	0
781	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. Journal of the American Heart Association, 2017, 6, .	1.6	0
782	Concerns about the European Society of Cardiology atrial fibrillation guidelines: reply. Europace, 2018, 20, 216-216.	0.7	0
783	Deciphering the Unknowns of Stroke After Aortic Valve Interventions. Journal of the American College of Cardiology, 2018, 72, 2427-2430.	1.2	0
784	Interpretation of results of pooled analysis of individual patient data. Lancet, The, 2018, 392, 817-818.	6.3	0
785	Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery. Annals of Internal Medicine, 2018, 168, 289.	2.0	0
786	TAVR for the Treatment of Degenerated Aortic Bioprostheses. Journal of the American College of Cardiology, 2019, 73, 2656-2659.	1.2	0
787	Mitral Regurgitation and Evolving Transcatheter Treatments. Journal of the American College of Cardiology, 2019, 73, 1353-1357.	1.2	0
788	Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement. Structural Heart, 2019, 3, 220-228.	0.2	0
789	Percutaneous patent foramen ovale closure during live case demonstrations. Catheterization and Cardiovascular Interventions, 2019, 93, 982-988.	0.7	0
790	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI. JACC: Cardiovascular Interventions, 2020, 13, 2314-2316.	1.1	0
791	Pulmonary Artery Pressure Ventricularization in a Patient With Carcinoid Heart Disease. JACC: Case Reports, 2020, 2, 1200-1204.	0.3	0
792	Adding a Clasp to the Toolbox for Transcatheter Mitral Valve Repair. JACC: Cardiovascular Interventions, 2020, 13, 2358-2360.	1.1	0

#	ARTICLE	IF	CITATIONS
793	Relationship between arterial remodelling and serial changes in coronary atherosclerosis by intravascular ultrasound: an analysis of the IBIS-4 study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1054-1062.	0.5	0
794	Predilatation and paravalvular leakage risk in TAVR – Authors' reply. <i>Lancet, The</i> , 2020, 396, 600-601.	6.3	0
795	Synergistic Effect of 2 Transcatheter Tricuspid Valve Treatment Modalities. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e5-e7.	1.1	0
796	Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions. <i>EuroIntervention</i> , 2021, 16, 1326-1332.	1.4	0
797	Learning From Failure at the CUTTING-EDGE of Transcatheter Mitral Valve Therapies. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2022-2026.	1.1	0
798	Multimodality Imaging for Evaluation of Bicaval Valved Stent Implantation in Severe Tricuspid Regurgitation. <i>JACC: Case Reports</i> , 2021, 3, 1512-1518.	0.3	0
799	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. <i>Preventive Medicine Reports</i> , 2021, 24, 101583.	0.8	0
800	Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 1-18.		0
801	Sports engagement and age at first myocardial infarction in men under 55 years of age. <i>PLoS ONE</i> , 2017, 12, e0184035.	1.1	0
802	Stent Technology. , 2018, , 137-159.		0
803	2019 – A leap year for valvular heart disease. <i>EuroIntervention</i> , 2019, 15, 821-823.	1.4	0
804	Will the Evolut Low Risk trial change my practice?. <i>EuroIntervention</i> , 2019, 15, e1072-e1076.	1.4	0
805	Are all DES equal at 10-year follow-up?. <i>EuroIntervention</i> , 2019, 15, e945-e947.	1.4	0
806	Cumulative evidence on DAPT: different strategies, heterogenous populations, complex decisions. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 65-67.	1.4	0
807	Impact of first medical contact to revascularisation time on long-term clinical outcomes in ST-segment elevation myocardial infarction patients. <i>Swiss Medical Weekly</i> , 2020, 150, w20368.	0.8	0
808	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e023143.	1.6	0
809	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. , 2022, 1, 100033.		0
810	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1963-1965.	1.2	0

#	ARTICLE	IF	CITATIONS
811	Cardiovascular meta-analyses: foolâ€™s gold or gold for fools?. European Heart Journal, 0, , .	1.0	0